Abstract
The electrophysiologic effects of a new anti-arrhythmic agent NE-10064 were compared with known class III drugs, E-4031 and sotalol, in sheep Purkinje fibres paced at 1 Hz under normal and simulated ischaemic conditions. NE-10064 0.3-3 microM and sotalol 0.3-300 microM prolonged action potential duration at 90% of repolarization (APD90) and effective refractory period (ERP) concentration dependently without affecting APD50 under normal conditions. E-4031 0.3-300 microM prolonged APD50, APD90, and ERP concentration dependently. Percentage increases in APD90 of 20 +/- 6, 27 +/- 6, and 33 +/- 9 were calculated for NE-10064 3 microM, sotalol 300 microM, and E-4031 1 microM under normal conditions, respectively. The concentration-response curves for all three drugs were shifted to the right under simulated ischaemic conditions. The shift was more marked for NE-10064 and sotalol. Percentage increases in APD90 of 8 +/- 5, 13 +/- 2, and 23 +/- 4 were observed with NE-10064 3 microM, sotalol 300 microM, and E-4031 1 microM during simulated ischaemia. NE-10064 exhibits electrophysiologic characteristics similar to those of known class III agents. Its ability to prolong APD90 under normal conditions may explain its antiarrhythmic action i...Continue Reading
Citations
Jun 12, 2003·European Journal of Pharmacology·János TakácsJulius Gy Papp
Aug 10, 1999·European Journal of Pharmacology·Y XueK Hashimoto
Jan 19, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J J BaoA Shuja
Sep 15, 2000·Journal of the American College of Cardiology·J MérotF Charpentier
Feb 2, 2000·Proceedings of the Society for Experimental Biology and Medicine·R R BrooksD R Kostreva
Apr 29, 1998·Journal of Cardiovascular Electrophysiology·J M Pinto, P A Boyden
Apr 16, 1998·The American Journal of Cardiology·R KaramA Moore
Apr 16, 1998·The American Journal of Cardiology·A J CammC M Pratt
Aug 9, 2005·European Journal of Pharmacology·Joffrey DucroqJean-Louis Gérard
Apr 25, 2000·Journal of Cardiovascular Pharmacology·P GeelenJ Turgeon
Dec 1, 1996·Journal of Cardiovascular Pharmacology·A P DrexlerR R Brooks
Dec 22, 1999·Journal of Cardiovascular Pharmacology·X Q QiP Dorian
Jul 1, 1997·Journal of Cardiovascular Pharmacology and Therapeutics·P D WestT J Campbell
Aug 15, 2000·Journal of Cardiovascular Pharmacology·V Nand, S A Doggrell
Jun 27, 2021·European Journal of Pharmacology·Moawiah M Naffaa, Ola A Al-Ewaidat